Search Results - "Xuereb, L."

A phase Ib dose allocation study of oral administration of lucitanib given in combination with fulvestrant in patients with estrogen receptor-positive and FGFR1-amplified or non-amplified metastatic breast cancer by Campone, M., Bachelot, T., Penault-Llorca, F., Pallis, A., Agrapart, V., Pierrat, M. J., Poirot, C., Dubois, F., Xuereb, L., Bossard, C. J., Guigal-Stephan, N., Lockhart, B., Andre, F.

“…Purpose The primary objective of this multicentric dose allocation and dose expansion study was to determine the MTD and the DLTs of the lucitanib (a tyrosine…”
Get full text

Effect of KRAS codon 12 or 13 mutations on survival with trifluridine/tipiracil in pretreated metastatic colorectal cancer: a meta-analysis by Yoshino, T., Van Cutsem, E., Li, J., Shen, L., Kim, T.W., Sriuranpong, V., Xuereb, L., Aubel, P., Fougeray, R., Cattan, V., Amellal, N., Ohtsu, A., Mayer, R.J.

“…KRAS gene mutations can predict prognosis and treatment response in patients with metastatic colorectal cancer (mCRC). We undertook a meta-analysis of three…”
Get full text

Lucitanib for the treatment of HR+ HER2- metastatic breast cancer (MBC) patients (pts): Results from the multicohort phase II FINESSE trial by Hui, R., Pearson, A., Cortes Castan, J., Campbell, C., Poirot, C., Azim, H.A., Fumagalli, D., Lambertini, M., Daly, F., Arahmani, A., Perez-Garcia, J., Aftimos, P.G., Bedard, P., Xuereb, L., Loibl, S., Loi, S., Pierrat, M.-J., Turner, N.C., André, F., Curigliano, G.

Get full text

Reoperation for Bleeding Does Not Adversely Impact Long-Term Outcomes in LVAD Recipients by Xuereb, L, Kaur, B, Akrawe, S, Rashty, J, Nemeh, H.W, Borgi, J, Lanfear, D.E, Williams, C.T, Paone, G, Morgan, J.A

Get full text

Does Preoperative Atrial Fibrillation Increase the Incidence of Thromboembolic Complications in Patients Supported with Long-Term LVADs? by Xuereb, L, Kaur, B, Akrawe, S, Nemeh, H.W, Borgi, J, Lanfear, D.E, Williams, C.T, Paone, G, Morgan, J.A

Get full text

Drive Line Infections Are Not Associated with an Increased Incidence of Thromboembolic Complications in Patients on Continuous Flow LVAD Support by Xuereb, L, Kaur, B, Akrawe, S, Rashty, J, Nemeh, H.W, Borgi, J, Tita, C, Selektor, Y, Velez, M, Lanfear, D.E, Williams, C.T, Paone, G, Morgan, J.A

Get full text

P.188 Anaesthetic management of a parturient with DAO enzyme deficiency, postural orthostatic tachycardia syndrome and joint hypermobility by Xuereb, L. Borg, Halder, S.

Get full text

Aging and Obesity Induce Distinct Gene Expression Adaptation in the Liver of C57BL/6J Mice by Capel, F., Delmotte, M.H., Brun, M., Lonchampt, M., De Fanti, B., Xuereb, L., Baschet, L., Rolland, G., Galizzi, J.P., Lockhart, B., Ktorza, A., Dacquet, C.

“…Background: Aging and obesity induce complex transcriptomic changes in the liver, promoting the development of insulin resistance and type 2 diabetes. In spite…”
Get full text

Age alters peripheral vascular endothelial function without affecting coronary flow reserve in healthy volunteers by Bouly, M, Bourguignon, M.P, Ley, S, Xuereb, L, Bernhardt, P, Tyl, B

“…Abstract Background Age is a key risk factor contributing to vascular endothelial dysfunction. Whether the impact of ageing is uniform on various vascular beds…”
Get full text

Abstract P1-09-11: A phase Ib study of oral administration of lucitanib in combination with fulvestrant in patients with HR+ metastatic breast cancer (mBC) by Campone, M, Bachelot, T, Penault-Llorca, F, Pallis, A, Agrapart, V, Pierrat, M-J, Poirot, C, Paux, G, Dubois, F, Xuereb, L, Robert, R, Andre, F

“…Abstract FGFR1 amplification could mediate resistance to endocrine therapy and FGFR1 inhibition reverses this resistance. This phase Ib seeks to evaluate…”
Get full text

289PDLucitanib for the treatment of HR+ HER2- metastatic breast cancer (MBC) patients (pts): Results from the multicohort phase II FINESSE trial by Hui, R, Pearson, A, Cortes Castan, J, Campbell, C, Poirot, C, Azim, H A, Fumagalli, D, Lambertini, M, Daly, F, Arahmani, A, Perez-Garcia, J, Aftimos, P G, Bedard, P, Xuereb, L, Loibl, S, Loi, S, Pierrat, M-J, Turner, N C, André, F, Curigliano, G

Get full text

Calcitonin receptor isoforms expressed in the developing rat kidney by Tikellis, Christos, Xuereb, Loredanna, Casley, David, Brasier, Geoffrey, Cooper, Mark E., Wookey, Peter J.

“…Calcitonin receptor isoforms expressed in the developing rat kidney. Development in the metanephric-kidney transition period involves the precise expression of…”
Get full text

Novel hexad repeats conserved in a putative transporter with restricted expression in cell types associated with growth, calcium exchange and homeostasis by Brasier, Geoffrey, Tikellis, Christos, Xuereb, Loredanna, Craigie, Jillian, Casley, David, Kovacs, Christopher S, Fudge, Neva J, Kalnins, Renate, Cooper, Mark E, Wookey, Peter J

“…A transport protein is described with 12 transmembrane spans. Within the cytoplasmic amino-terminal domain, several novel hexad repeats are conserved in human,…”
Get full text